US20040067260A1 - Stable aqueous suspension - Google Patents
Stable aqueous suspension Download PDFInfo
- Publication number
- US20040067260A1 US20040067260A1 US10/678,557 US67855703A US2004067260A1 US 20040067260 A1 US20040067260 A1 US 20040067260A1 US 67855703 A US67855703 A US 67855703A US 2004067260 A1 US2004067260 A1 US 2004067260A1
- Authority
- US
- United States
- Prior art keywords
- oil
- group
- mixture
- foregoing
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *c1cc2occ(-c3ccc(O)cc3)c(=O)c2c(*)c1* Chemical compound *c1cc2occ(-c3ccc(O)cc3)c(=O)c2c(*)c1* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/003—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/02—Oxidoreductases acting on diphenols and related substances as donors (1.10) with a cytochrome as acceptor (1.10.2)
- C12Y110/02002—Ubiquinol-cytochrome-c reductase (1.10.2.2), i.e. electron-transport-complex-III
Definitions
- This invention relates to a stable aqueous suspension comprising a nutrient, as well as to a method of rendering a normally hydrophobic nutritional compound or ingredient dispersible in water or in an aqueous system.
- Nutritional compounds i.e. nutritional supplements, have been shown to help prevent the onset of undesirable conditions in man. These substances have been identified as either essential to human health (e.g. vitamins), or may, based on the increasing compilation of studies, play a role in maintaining health. For example, phytosterol and/or phytostanol esters have been shown to reduce serum cholesterol levels in man (mammals) upon consumption, and subsequent digestion in the gut. The mechanism for this is not completely known.
- scientists theorize that these compounds block absorption of cholesterol produced and released from the body through the normal hepatic function, or consumed as a component of food. In reducing serum cholesterol levels, current wisdom deduces that heart and circulatory health may be maintained by preventing such conditions as arteriosclerosis, myocardial infarction, etc.
- Nutritional ingredients such as lutein
- the nutritional ingredients are typically hydrophobic and are not ordinarily dispersible in aqueous systems because they are only slightly water or oil soluble, if to any degree at all.
- the nutritional ingredients are desirable for use in beverages and cosmetics, in the form of aqueous suspensions, dispersions, or liposomes. Accordingly, a means for rendering these ingredients water dispersible or dispersible in an aqueous system is needed and desired.
- This invention relates to a stable suspension comprising a nutrient or nutritional ingredient.
- the nutrient is in an ester form and is associated with a dispersion aid and a dispersion agent.
- This invention involves a stable aqueous suspension which comprises a nutrient or a nutritional compound or ingredient.
- a suitable nutrient or nutritional ingredient is one which is suitable for therapeutic treatment of an animal, e.g. a human being, by ingestion, e.g. via a beverage, or by topical application, e.g. via a lotion or cream, but which is unfortunately typically insoluble or only slightly soluble in water at room temperature, e.g. 20° C. to 25° C., i.e. it is typically hydrophobic. It is these ingredients which are the subject of this invention.
- Some suitable nutrients or nutritional ingredients include (1) a compound of the formula,
- R is OH, ⁇ -glucoside, 6′′-O-acetylglucoside, or 6′′-O-malonylglucoside;
- R′ is H or OH; and
- R′′ is H or OCH 3 ;
- isoflavone e.g. a soybean derived isoflavone, and a substituted isoflavone, such as daidzein, genistein and glycitein
- a stigmasterol sitosterol, fucosterol, brassicasterol, campesterol, clionasterol, desmosterol, chalinosterol, poriferasterol, (5) a phytostanol, e.g. ⁇ or ⁇ sitostanol, campestanol, brassicastanol, clionastanol, stigmastanol, desmostanol, chalinostanol, poriferastanol, 22, 23 dihydrobrassicastanol, etc. and (6) a mixture of any of the foregoing ingredients.
- a phytostanol e.g. ⁇ or ⁇ sitostanol, campestanol, brassicastanol, clionastanol, stigmastanol, desmostanol, chalinostanol, poriferastanol, 22, 23 dihydrobrassicastanol, etc.
- a particular nutrient or mixture of nutritional ingredients is present in the inventive aqueous dispersions or suspensions in an effective nutritional amount, that is an amount which causes its desired nutritional or therapeutic effect.
- the term “amount” as used herein refers to quantity or concentration as appropriate to the context.
- the amount of nutrient that constitutes a nutritional amount varies according to factors such as potency of the particular ingredient or mixture of ingredients, the mode of administration and the mechanical system used to administer the dispersion.
- a normally effective amount of a particular nutrient can be selected by those of ordinary skill in the art with due consideration of such factors.
- a nutritionally effective amount will be from 0.005 parts by weight to about 25 parts by weight based on 100 parts by weight of the dispersion or suspension.
- a suitable aqueous system or medium is selected.
- a suitable aqueous system or medium for the dispersions or suspensions of this invention include water and an aqueous solution of an organic alcohol of 1 to 6 carbon atoms, e.g. ethanol, propylene glycol, glycerin, etc., and a mixture of the foregoing; present in an amount of up to 10 percent (10%) by weight.
- the aqueous system is one which will permit a stable dispersion or suspension to be formed therein when combined with the selected nutrient or mixture of nutrients, which in turn is destined to be in the form of at least a mono-ester associated with a suitable dispersion aid.
- the aqueous system is present in an amount which affords the desired dispersion and is dependent upon the selected nutrient or mixture of nutritional ingredients with the selected dispersion aid. Typically, the aqueous system comprises 55 to 95 weight percent of the dispersion or suspension.
- the selected nutrient must first be converted to an ester, e.g. a mono-, di-, tri-ester, etc., if it does not already exist as at least a mono-ester.
- an ester e.g. a mono-, di-, tri-ester, etc.
- Such conversion if required, is conventionally carried out.
- a suitable dispersion aid is selected, i.e. an agent which when combined or associated with the nutrient ester modifies such ester from its crystalline form or morphous form to a dissolved form.
- the then modified nutrient compound, i.e. ester can then be further formulated or treated, e.g. pulverized, particularized, homogenized, liquefied, dispersed in oil carrier, whereby it can be easily dispersed in water or an aqueous medium as a suspension.
- a suitable dispersion aid includes (1) a triglyceride, such as sunflower oil, soy bean oil, olive oil; a medium chain triglyceride i.e. triglycerides with mixed fatty acids of C 6 to C 12 lengths, such as sn-glyceryl-1-caprylate, -2-caprate, -3-caprylate, etc., and a mixture of any of the foregoing, (2) an essential oil extractive, such as orange oil, lime oil, clove oil, oregano oil, peppermint oil, cinnamon oil, etc., and a mixture of the foregoing; (3) night primrose oil; (4) fish oils; (5) and a mixture of any of the foregoing aids.
- a triglyceride such as sunflower oil, soy bean oil, olive oil
- a medium chain triglyceride i.e. triglycerides with mixed fatty acids of C 6 to C 12 lengths, such as sn-glyceryl-1-capry
- the nutrient in ester form is combined or mixed with the dispersion aid, typically at a temperature ranging from 20 to 80° C., e.g. 70-75° C., for 2 to 10 minutes to form the nutrient ester associated with the dispersion aid.
- association means that the nutrient ester has either reacted with the dispersion aid or has physically interacted with the dispersion aid whereby it is either mixed therewith, encapsulated, wholly or partially, thereby, or becomes part of the interstices thereof, solubilized or diluted.
- a suitable dispersion agent is selected from (1) a lecithin, derived from soybean or derived from egg which contain a complex mixture of phospholipids consisting mainly of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidic acid combined with varying amounts of other substances such as triglycerides: the lecithin can be of standard grade or can be modified or refined lecithin e.g. deoiled, hydrogenated, hydroxylated, enzyme modified, acetylated, etc.; (2) a hydrocolloid, e.g.
- xanthan gum starch, pectin, gelatin, guar gum, carrageenan, methylcellulose, hydroxypropyl cellulose; (3) a surfactant, e.g. cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, polyglycerol esters, block copolymers of propylene oxide, ethylene oxide; (4) a mixture of any of the forgoing dispersion agents.
- a surfactant e.g. cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, polyglycerol esters, block copolymers of propylene oxide, ethylene oxide
- (4) a mixture of any of the forgoing dispersion agents e.g. cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, polyglycerol esters, block copolymers of propylene oxide, ethylene oxide.
- An aqueous dispersion of the selected nutrient/aid combination utilizes the dispersion agent in an amount effective to form and stabilize the resultant aqueous dispersion relative to an identical aqueous formulation not containing the dispersion agent, such that the active ingredient does not settle, cream or flocculate after agitation so quickly as to prevent reproducibility, e.g. reproducible dosing.
- Reproducible application, e.g. dosing can be achieved if the resultant aqueous suspension is substantially uniform for minimally 1 to 2 hours after agitation thereof.
- the particular amount of dispersion agent that constitutes an effective amount is dependent upon the particular dispersion agent, the particular aqueous system or medium employed and the particular nutritional ingredient/aid combination, or mixture of ingredients employed. It is therefore not practical to enumerate a specific effective amount for use with specific dispersions or formulations of the invention, but such amount can readily be determined by those of ordinary skill in the art with due consideration of the factors set forth above.
- the dispersion agent can be present in a formulation in an amount from about 0.01 percent by weight to about 20 percent by weight, more preferably about 0.05 percent to about 10 percent by weight, most preferably 0.5 percent to 5 percent by weight, based on the total weight of the dispersion or formulation.
- the dispersion aid e.g. sunflower oil
- the active ingredient or nutritional agent e.g. phytosterol esters
- the combination is added to water containing dispersion agents, and is agitated thereto to form a mixture.
- the resultant mixture is then subjected to a high shear treatment using any commercially available equipment, e.g.
- Microfluidics M110 at a shear pressure of 6500 to 24,000 psi, and preferably at a shear pressure of 7000 to 20,000 psi, and most preferably at a shear 10,000 to 12,000 psi, whereby a particle size of the active ingredient typically is less than 500 nm, preferably less than 300 nm, most preferably less than 250 nm, to form the desired aqueous dispersion or suspension.
- the resultant aqueous nutrient dispersion can then be further formulated and administered to a patient, e.g. a mammal such as a human being, by any conventional means, such as topically, orally; etc.
- a patient e.g. a mammal such as a human being
- the dispersion or suspension is combined with other drugs, adjuvants, etc. in the form of a cream or lotion, e.g. a cosmetic, or in the form of a liquid, e.g. a beverage.
- SELIN® brand phytosterol fatty acid esters from Cognis (6.0 g) was dissolved in 24.0 g of NUSUN® oil, from Archer Daniels Midland, a high oleic acid sunflower oil, at 36° C.
- the resultant solution was added to an aqueous system comprising 78.5 percent by weight of deionized water (157 g), 4.0 percent by weight BLENDMAX K® lecithin from Central Soya (8 g) and 2.5 percent polysorbate 80 (5 g).
- the resultant mixture was treated two times with a Microfluidizer® M110T from Microfluidics at 8,000 psi shear pressure to obtain a stable dispersion.
- Example 1 The procedure of Example 1 was repeated using 15 g of SELIN®, 15 g of NUSUN® oil, 157 g of deionized water, 8 g of BLENDMAX K®, and 5 g of polysorbate 80 to obtain a stable dispersion.
- SELIN® (6 g) was combined with NUSUN® oil (24 g) and heated at 60° C. for 15 minutes to form a solution.
- Deionized water 155.8 g
- polysorbate 80 (5 g) were mixed together and heated at 60° C. for 15 minutes and then combined with the solution.
- BLENDMAX K® lecithin 8 g
- citric acid 6 g
- potassium sorbate 0.6 g
- Example 3 The procedure of Example 3 was repeated with 10 g of SELIN®, 20 g of NUSUN® oil, 155.8 g of deionized water, 8 g of BLENDMAX K®, 5 g of polysorbate 80, 0.6 g of citric acid and 0.6 g of potassium sorbate. A mean particle size of 194.6 nm of the stable dispersion was obtained.
- Example 5 The procedure of Example 5 was repeated for lutein esters A(g) B(g) Deionized Water 72.9 67.9 BLENDMAX ® 4.0 4.0 Polysorbate 80 2.5 2.5 NUSUN ® Oil 19.8 24.75 Citric acid 0.3 0.3 Potassium sorbate 0.3 0.3 Xangold ® Lutein esters 0.2 0.25
- Example 7 The procedure of Example 7 was repeated using 3.75 g of Xangold® lutein esters and 21.25 g of olive oil instead of orange oil to obtain a stable dispersion.
Abstract
An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.
Description
- 1. Field of the Invention
- This invention relates to a stable aqueous suspension comprising a nutrient, as well as to a method of rendering a normally hydrophobic nutritional compound or ingredient dispersible in water or in an aqueous system.
- 2. Description of the Related Art
- Nutritional compounds, i.e. nutritional supplements, have been shown to help prevent the onset of undesirable conditions in man. These substances have been identified as either essential to human health (e.g. vitamins), or may, based on the increasing compilation of studies, play a role in maintaining health. For example, phytosterol and/or phytostanol esters have been shown to reduce serum cholesterol levels in man (mammals) upon consumption, and subsequent digestion in the gut. The mechanism for this is not completely known. Scientists theorize that these compounds block absorption of cholesterol produced and released from the body through the normal hepatic function, or consumed as a component of food. In reducing serum cholesterol levels, current wisdom deduces that heart and circulatory health may be maintained by preventing such conditions as arteriosclerosis, myocardial infarction, etc.
- Nutritional ingredients, such as lutein, are currently available in tablets or other dry forms because heretofore they could not be satisfactorily dispersed in water. The nutritional ingredients, such as the phytosterols, phytostanols, lutein, isoflavones, Coenzyme Q10, are typically hydrophobic and are not ordinarily dispersible in aqueous systems because they are only slightly water or oil soluble, if to any degree at all.
- The nutritional ingredients are desirable for use in beverages and cosmetics, in the form of aqueous suspensions, dispersions, or liposomes. Accordingly, a means for rendering these ingredients water dispersible or dispersible in an aqueous system is needed and desired.
- This invention relates to a stable suspension comprising a nutrient or nutritional ingredient. In particular, the nutrient is in an ester form and is associated with a dispersion aid and a dispersion agent.
- This invention involves a stable aqueous suspension which comprises a nutrient or a nutritional compound or ingredient.
- A suitable nutrient or nutritional ingredient is one which is suitable for therapeutic treatment of an animal, e.g. a human being, by ingestion, e.g. via a beverage, or by topical application, e.g. via a lotion or cream, but which is unfortunately typically insoluble or only slightly soluble in water at room temperature, e.g. 20° C. to 25° C., i.e. it is typically hydrophobic. It is these ingredients which are the subject of this invention. Some suitable nutrients or nutritional ingredients include (1) a compound of the formula,
- where R is OH, β-glucoside, 6″-O-acetylglucoside, or 6″-O-malonylglucoside; R′ is H or OH; and R″ is H or OCH3; such as isoflavone, e.g. a soybean derived isoflavone, and a substituted isoflavone, such as daidzein, genistein and glycitein; (2) lutein, (3) a Coenzyme Qn, where n is an integer of 1-12, e.g. Coenzyme Q10, (4) a phytosterol, e.g. a stigmasterol, sitosterol, fucosterol, brassicasterol, campesterol, clionasterol, desmosterol, chalinosterol, poriferasterol, (5) a phytostanol, e.g. α or β sitostanol, campestanol, brassicastanol, clionastanol, stigmastanol, desmostanol, chalinostanol, poriferastanol, 22, 23 dihydrobrassicastanol, etc. and (6) a mixture of any of the foregoing ingredients.
- For purposes of the dispersions of this invention, which are intended for therapeutic use or as additives in association with a therapeutic treatment of animals, e.g. a human, a particular nutrient or mixture of nutritional ingredients is present in the inventive aqueous dispersions or suspensions in an effective nutritional amount, that is an amount which causes its desired nutritional or therapeutic effect.
- The term “amount” as used herein refers to quantity or concentration as appropriate to the context. The amount of nutrient that constitutes a nutritional amount varies according to factors such as potency of the particular ingredient or mixture of ingredients, the mode of administration and the mechanical system used to administer the dispersion. A normally effective amount of a particular nutrient can be selected by those of ordinary skill in the art with due consideration of such factors. Generally, a nutritionally effective amount will be from 0.005 parts by weight to about 25 parts by weight based on 100 parts by weight of the dispersion or suspension.
- A suitable aqueous system or medium is selected. A suitable aqueous system or medium for the dispersions or suspensions of this invention include water and an aqueous solution of an organic alcohol of 1 to 6 carbon atoms, e.g. ethanol, propylene glycol, glycerin, etc., and a mixture of the foregoing; present in an amount of up to 10 percent (10%) by weight. The aqueous system is one which will permit a stable dispersion or suspension to be formed therein when combined with the selected nutrient or mixture of nutrients, which in turn is destined to be in the form of at least a mono-ester associated with a suitable dispersion aid. The aqueous system is present in an amount which affords the desired dispersion and is dependent upon the selected nutrient or mixture of nutritional ingredients with the selected dispersion aid. Typically, the aqueous system comprises 55 to 95 weight percent of the dispersion or suspension.
- The selected nutrient must first be converted to an ester, e.g. a mono-, di-, tri-ester, etc., if it does not already exist as at least a mono-ester. Such conversion, if required, is conventionally carried out. In this regard, reference is made to such standard text as Briehler, and Pearson, “Survey of Organic Synthesis”, Volumes 1 and 2, John Wiley & Sons.
- Additionally, reference is made to Ingmar Westar et al., WO 09956558; M. P. van Amerongen et al., EP 00911385 A1 which describes the preparation of stanol, phytosterol and phytostanol esters.
- A suitable dispersion aid is selected, i.e. an agent which when combined or associated with the nutrient ester modifies such ester from its crystalline form or morphous form to a dissolved form. The then modified nutrient compound, i.e. ester, can then be further formulated or treated, e.g. pulverized, particularized, homogenized, liquefied, dispersed in oil carrier, whereby it can be easily dispersed in water or an aqueous medium as a suspension.
- A suitable dispersion aid includes (1) a triglyceride, such as sunflower oil, soy bean oil, olive oil; a medium chain triglyceride i.e. triglycerides with mixed fatty acids of C6 to C12 lengths, such as sn-glyceryl-1-caprylate, -2-caprate, -3-caprylate, etc., and a mixture of any of the foregoing, (2) an essential oil extractive, such as orange oil, lime oil, clove oil, oregano oil, peppermint oil, cinnamon oil, etc., and a mixture of the foregoing; (3) night primrose oil; (4) fish oils; (5) and a mixture of any of the foregoing aids.
- The nutrient in ester form is combined or mixed with the dispersion aid, typically at a temperature ranging from 20 to 80° C., e.g. 70-75° C., for 2 to 10 minutes to form the nutrient ester associated with the dispersion aid. By “associate” or “associated” means that the nutrient ester has either reacted with the dispersion aid or has physically interacted with the dispersion aid whereby it is either mixed therewith, encapsulated, wholly or partially, thereby, or becomes part of the interstices thereof, solubilized or diluted.
- A suitable dispersion agent is selected from (1) a lecithin, derived from soybean or derived from egg which contain a complex mixture of phospholipids consisting mainly of phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidic acid combined with varying amounts of other substances such as triglycerides: the lecithin can be of standard grade or can be modified or refined lecithin e.g. deoiled, hydrogenated, hydroxylated, enzyme modified, acetylated, etc.; (2) a hydrocolloid, e.g. xanthan gum, starch, pectin, gelatin, guar gum, carrageenan, methylcellulose, hydroxypropyl cellulose; (3) a surfactant, e.g. cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, polyglycerol esters, block copolymers of propylene oxide, ethylene oxide; (4) a mixture of any of the forgoing dispersion agents.
- An aqueous dispersion of the selected nutrient/aid combination utilizes the dispersion agent in an amount effective to form and stabilize the resultant aqueous dispersion relative to an identical aqueous formulation not containing the dispersion agent, such that the active ingredient does not settle, cream or flocculate after agitation so quickly as to prevent reproducibility, e.g. reproducible dosing. Reproducible application, e.g. dosing, can be achieved if the resultant aqueous suspension is substantially uniform for minimally 1 to 2 hours after agitation thereof. The particular amount of dispersion agent that constitutes an effective amount is dependent upon the particular dispersion agent, the particular aqueous system or medium employed and the particular nutritional ingredient/aid combination, or mixture of ingredients employed. It is therefore not practical to enumerate a specific effective amount for use with specific dispersions or formulations of the invention, but such amount can readily be determined by those of ordinary skill in the art with due consideration of the factors set forth above. Generally, however, the dispersion agent can be present in a formulation in an amount from about 0.01 percent by weight to about 20 percent by weight, more preferably about 0.05 percent to about 10 percent by weight, most preferably 0.5 percent to 5 percent by weight, based on the total weight of the dispersion or formulation.
- Typically, the dispersion aid, e.g. sunflower oil, is combined with the active ingredient or nutritional agent, e.g. phytosterol esters, at a temperature of 20 to 80° C. and is mixed for 2 to 10 minutes. Thereafter the combination is added to water containing dispersion agents, and is agitated thereto to form a mixture. The resultant mixture is then subjected to a high shear treatment using any commercially available equipment, e.g. Microfluidics M110, at a shear pressure of 6500 to 24,000 psi, and preferably at a shear pressure of 7000 to 20,000 psi, and most preferably at a shear 10,000 to 12,000 psi, whereby a particle size of the active ingredient typically is less than 500 nm, preferably less than 300 nm, most preferably less than 250 nm, to form the desired aqueous dispersion or suspension.
- It is noted that the procedure described above can be modified, namely the order of addition of the nutrient/aid combination, dispersion agent, and aqueous system to form the initial aqueous mixture, i.e. preceding to the described high shear treatment of the mixture.
- The resultant aqueous nutrient dispersion can then be further formulated and administered to a patient, e.g. a mammal such as a human being, by any conventional means, such as topically, orally; etc. Typically the dispersion or suspension is combined with other drugs, adjuvants, etc. in the form of a cream or lotion, e.g. a cosmetic, or in the form of a liquid, e.g. a beverage.
- SELIN® brand phytosterol fatty acid esters from Cognis (6.0 g) was dissolved in 24.0 g of NUSUN® oil, from Archer Daniels Midland, a high oleic acid sunflower oil, at 36° C. The resultant solution was added to an aqueous system comprising 78.5 percent by weight of deionized water (157 g), 4.0 percent by weight BLENDMAX K® lecithin from Central Soya (8 g) and 2.5 percent polysorbate 80 (5 g). The resultant mixture was treated two times with a Microfluidizer® M110T from Microfluidics at 8,000 psi shear pressure to obtain a stable dispersion.
- The procedure of Example 1 was repeated using 15 g of SELIN®, 15 g of NUSUN® oil, 157 g of deionized water, 8 g of BLENDMAX K®, and 5 g of polysorbate 80 to obtain a stable dispersion.
- SELIN® (6 g) was combined with NUSUN® oil (24 g) and heated at 60° C. for 15 minutes to form a solution. Deionized water (155.8 g) and polysorbate 80 (5 g) were mixed together and heated at 60° C. for 15 minutes and then combined with the solution. BLENDMAX K® lecithin (8 g), citric acid (0.6 g) and potassium sorbate (0.6 g) were added to the combined solution with mixing and then the resultant mixture was passed through a M110T Microfluidizer®, two times at a shear pressure of 8,000 psi. A mean particle size of the stable dispersion of 178.3 nm was obtained.
- The procedure of Example 3 was repeated with 10 g of SELIN®, 20 g of NUSUN® oil, 155.8 g of deionized water, 8 g of BLENDMAX K®, 5 g of polysorbate 80, 0.6 g of citric acid and 0.6 g of potassium sorbate. A mean particle size of 194.6 nm of the stable dispersion was obtained.
- An experiment was conducted to see how high a percentage of the phytosterol esters could be incorporated into a stable dispersion. The general procedure was to combine BLENDMAX K®, Polysorbate 80, NUSUN® oil and SELIN® and mix these components thoroughly at a temperature of 60°-65° C. To this mix was added deionized water, and the resultant mixture was mixed with a Silverson® high shear mixer. While mixing, citric acid and potassium sorbate were added. Once the mixture became uniform, it was passed twice through a M110T Microfluidizer® at a shear pressure of 8,000 psi. The highest percentage of the SELIN in a stable dispersion obtained was 10.0 percent by weight, using the following weight percentages of the ingredients.
Deionized Water 72.9 BLENDMAX ® 4.0 Polysorbate 80 2.5 NUSUN ® Oil 10.0 SELIN ® 10.0 Citric acid 0.3 Potassium sorbate 0.3 - The procedure of Example 5 was repeated for lutein esters
A(g) B(g) Deionized Water 72.9 67.9 BLENDMAX ® 4.0 4.0 Polysorbate 80 2.5 2.5 NUSUN ® Oil 19.8 24.75 Citric acid 0.3 0.3 Potassium sorbate 0.3 0.3 Xangold ® Lutein esters 0.2 0.25 - Stable dispersions were obtained.
- 7.5 g of Xangold®, a 15% lutein ester suspension in vegetable oil from Cognis, was dissolved with 17.5 g of orange oil at 65° C. 4.0 g of BLENDMAX K®, 2.5 g of Polysorbate 80 were added and heated at 65° C. for several minutes. To the heated mixture was added 67.9 g of Deionized water, 0.3 g citric acid, and 0.3 g potassium sorbate while mixing with a Silverson® high shear mixer. The resultant mixture was then passed twice through a M110 Microfluidizer® at a shear pressure of 10,000 psi to yield a stable dispersion.
- The procedure of Example 7 was repeated using 3.75 g of Xangold® lutein esters and 21.25 g of olive oil instead of orange oil to obtain a stable dispersion.
Claims (19)
1. An aqueous suspension of a hydrophobic nutrient which comprises,
the nutrient in ester form associated with a dispersion aid selected from the group consisting of a triglyceride, an essential oil extractive, night primrose oil, fish oil, and a mixture of any of the foregoing dispersion aids;
a dispersion agent: and
an aqueous medium into which said associated nutrient is suspended.
2. The suspension as defined in claim 1 , wherein said associated nutrient is in a fully dispersed, uniform form in the aqueous medium.
3. The suspension as defined in claim 2 , wherein the particles size of said fully dispersed, uniform form ranges from 50 to 400 nm.
4. The suspension as defined in claim 1 , wherein said ester is an ester of a nutritional compound selected from the group consisting of (a) a phytosterol selected from the group consisting of stigmasterol, sitosterol, fucosterol, brassicasterol, campesterol, clionasterol, desmosterol, chalinosterol, poriferasterol, and any mixture of the foregoing phytosterols; (b) a phytostanol, selected from the group consisting of e.g. α sitostanol or β sitostanol, campestanol, brassicastanol, clionastanol, stigmastanol, desmostanol, chalinostanol, poriferastanol, 22, 23 dihydrobrassicastanol and any mixture of the foregoing phytostanols; (c) lutein, (d) Coenzyme Q10, (e) isoflavones, (f) and a mixture of any of the foregoing esters.
5. The suspension as defined in claim 1 , wherein said triglyceride is selected from the group consisting of sunflower oil, soy bean oil, olive oil, a medium chain triglyceride, selected from the group containing fatty acids ranging from C6 to C12, and a mixture of any of the foregoing triglycerides.
6. The suspension as defined in claim 1 , wherein said essential oil extractive is one selected from the group consisting of orange oil, lime oil, clove oil, oregano oil, peppermint oil, cinnamon oil, and a mixture of any of the foregoing extractives.
7. The suspension as defined in claim 1 , wherein said dispersion agent is selected from the group consisting of (a) a lecithin, (b) a hydrocolloid, (c) a surfactant and (d) a mixture of any of the foregoing dispersion agents.
8. The suspension as defined in claim 7 , wherein said lecithin is selected from the group consisting of lecithin derived from soybean and lecithin derived from egg.
9. The suspension as defined in claim 7 , wherein said hydrocolloid is selected from a group consisting of xanthan gum, starch, pectin, gelatin, guar gum, carrageenan, methylcellulose, hydroxypropyl cellulose and a mixture of the foregoing hydrocolloids.
10. The suspension as defined in claim 7 , wherein said surfactant is selected from the group consisting of cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, a polyglycerol ester, a block copolymer of propylene oxide, ethylene oxide and a mixture of any of the foregoing surfactants.
11. A method of rendering a hydrophobic nutritional compound water dispersible, which comprises:
(a) treating an ester form of the compound with a dispersion aid selected from the group consisting of a triglyceride, an essential oil extractive, night primrose oil, fish oil, and a mixture of any of the foregoing dispersion aids, to form a modified nutrient compound;
(b) combining a dispersion agent with said modified nutrient compound in an aqueous medium to form an aqueous suspension; and
treating said aqueous to a high shear force to form a stable aqueous suspension.
12. The method as defined in claim 11 , wherein said stable suspension has a mean particle size ranging from 50 to 400 nm.
13. The method as defined in claim 11 , wherein said ester is an ester of a nutritional compound selected from the group consisting of (a) a phytosterol, selected from the group consisting of stigmasterol, sitosterol, fucosterol, brassicasterol, campesterol, clionasterol, desmosterol, chalinosterol, poriferasterol, and any mixture of the foregoing phytosterols; (b) a phytostanol selected from the group consisting of α sitostanol, β sitostanol, campestanol, brassicastanol, clionastanol, stigmastanol, desmostanol, chalinostanol, poriferastanol, 22, 23 dihydrobrassicastanol, and any mixture of the foregoing phytostanols; (c) lutein, (d) Coenzyme Q10, (e) isoflavones, (f) and a mixture of any of the foregoing esters.
14. The method as defined in claim 11 , wherein said triglyceride is selected from the group consisting of sunflower oil, soy bean oil, olive oil, a medium chain triglyceride selected from the group containing fatty acids ranging from C6 to C12 and a mixture of any of the foregoing triglycerides.
15. The method as defined in claim 11 , wherein said essential oil extractive is one selected from the group consisting of orange oil, lime oil, clove oil, oregano oil, peppermint oil, cinnamon oil and a mixture of any of the foregoing extractives.
16. The method as defined in claim 11 , wherein said dispersion agent is selected from the group consisting of (a) a lecithin, (b) a hydrocolloid, (c) a surfactant and (d) a mixture of any of the foregoing dispersion agents.
17. The method as defined in claim 11 , wherein said lecithin is selected from the group consisting of a lecithin derived from soybean and a lecithin derived from egg.
18. The method as defined in claim 17 , wherein said hydrocolloid is selected from a group consisting of xanthan gum, starch, pectin, gelatin, guar gum, carrageenan, methylcellulose, hydroxypropyl cellulose and a mixture of the foregoing hydrocolloids.
19. The method as defined in claim 17 , wherein said surfactant is selected from the group consisting of cetylpyridinium chloride, polysorbate 80, sorbitan monostearate, a polyglycerol ester, a block copolymer of propylene oxide, ethylene oxide and a mixture of any of the foregoing surfactants.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/678,557 US20040067260A1 (en) | 2002-01-03 | 2003-10-03 | Stable aqueous suspension |
US11/936,430 US20080261927A1 (en) | 2002-01-03 | 2007-11-07 | Stable Aqueous Suspension |
US13/444,557 US20120195871A1 (en) | 2002-01-03 | 2012-04-11 | Stable aqueous suspension |
US13/848,314 US20130216512A1 (en) | 2002-01-03 | 2013-03-21 | Stable aqueous suspension |
US14/338,145 US9775910B2 (en) | 2002-01-03 | 2014-07-22 | Stable aqueous suspension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/037,573 US20030129253A1 (en) | 2002-01-03 | 2002-01-03 | Stable aqueous suspension |
US10/678,557 US20040067260A1 (en) | 2002-01-03 | 2003-10-03 | Stable aqueous suspension |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/037,573 Continuation US20030129253A1 (en) | 2002-01-03 | 2002-01-03 | Stable aqueous suspension |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/936,430 Continuation US20080261927A1 (en) | 2002-01-03 | 2007-11-07 | Stable Aqueous Suspension |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040067260A1 true US20040067260A1 (en) | 2004-04-08 |
Family
ID=21895069
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/037,573 Abandoned US20030129253A1 (en) | 2002-01-03 | 2002-01-03 | Stable aqueous suspension |
US10/678,557 Abandoned US20040067260A1 (en) | 2002-01-03 | 2003-10-03 | Stable aqueous suspension |
US11/936,430 Abandoned US20080261927A1 (en) | 2002-01-03 | 2007-11-07 | Stable Aqueous Suspension |
US13/444,557 Abandoned US20120195871A1 (en) | 2002-01-03 | 2012-04-11 | Stable aqueous suspension |
US13/848,314 Abandoned US20130216512A1 (en) | 2002-01-03 | 2013-03-21 | Stable aqueous suspension |
US14/338,145 Expired - Lifetime US9775910B2 (en) | 2002-01-03 | 2014-07-22 | Stable aqueous suspension |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/037,573 Abandoned US20030129253A1 (en) | 2002-01-03 | 2002-01-03 | Stable aqueous suspension |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/936,430 Abandoned US20080261927A1 (en) | 2002-01-03 | 2007-11-07 | Stable Aqueous Suspension |
US13/444,557 Abandoned US20120195871A1 (en) | 2002-01-03 | 2012-04-11 | Stable aqueous suspension |
US13/848,314 Abandoned US20130216512A1 (en) | 2002-01-03 | 2013-03-21 | Stable aqueous suspension |
US14/338,145 Expired - Lifetime US9775910B2 (en) | 2002-01-03 | 2014-07-22 | Stable aqueous suspension |
Country Status (3)
Country | Link |
---|---|
US (6) | US20030129253A1 (en) |
AU (1) | AU2002364054A1 (en) |
WO (1) | WO2003057157A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088645A1 (en) * | 2004-10-22 | 2006-04-27 | Access Business Group International Llc | Omega-3 food product and related method of manufacture |
US20070026126A1 (en) * | 2005-08-01 | 2007-02-01 | Bryan Hitchcock | Sterol fortified beverages |
US20070110874A1 (en) * | 2005-11-17 | 2007-05-17 | Pepsico, Inc. | Beverage clouding system and method |
US20080124387A1 (en) * | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
US20080299100A1 (en) * | 2004-01-22 | 2008-12-04 | University Of Miami | Topical Co-Enzyme Q10 Formulations and Methods of Use |
US20110020519A1 (en) * | 2008-01-04 | 2011-01-27 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110027247A1 (en) * | 2009-05-11 | 2011-02-03 | Niven Rajin Narain | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme q10) |
US20110052680A1 (en) * | 2008-01-04 | 2011-03-03 | AVERA, Inc. | Encapsulation of oxidatively unstable compounds |
US8454945B2 (en) | 2007-03-22 | 2013-06-04 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1549159E (en) * | 2002-06-12 | 2008-12-23 | Coca Cola Co | Beverages containing plant sterols |
US7306819B2 (en) * | 2002-06-12 | 2007-12-11 | The Coca-Cola Company | Beverages containing plant sterols |
WO2004103388A2 (en) * | 2003-05-22 | 2004-12-02 | Bioniche Life Sciences Inc. | Insect repellent |
DE20319249U1 (en) * | 2003-12-10 | 2004-12-30 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Lutein Concentrate |
FI123374B (en) * | 2011-03-25 | 2013-03-15 | Ravintoraisio Oy | New edible composition |
US20140127385A1 (en) * | 2012-11-04 | 2014-05-08 | Ingredient Innovations International | Stable Aqueous Dispersions of Poorly Soluble Crystalline Nutrients |
US20160143332A1 (en) | 2014-11-26 | 2016-05-26 | Omniactive Health Technologies Limited | Stable oil suspensions with enhanced bioavailability and compositions thereof |
ES2583162B1 (en) * | 2015-03-16 | 2017-07-10 | Suntory Beverage & Food Limited | Liquid compositions containing essential oils extracted from the citrus peel |
WO2017063660A1 (en) * | 2015-10-16 | 2017-04-20 | Raisio Nutrition Ltd | Capsules for lowering cholesterol |
WO2018187849A1 (en) * | 2017-04-13 | 2018-10-18 | Pharmako Biotechnologies Pty Limited | Cold-water-dispersible chemical delivery system |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886294A (en) * | 1973-03-12 | 1975-05-27 | Hoffmann La Roche | Carotenoid coloring compositions and preparation thereof |
US4048203A (en) * | 1976-12-06 | 1977-09-13 | Thomas Philip | Purification of lutein-fatty acid esters from plant materials |
US6190720B1 (en) * | 1999-06-15 | 2001-02-20 | Opta Food Ingredients, Inc. | Dispersible sterol compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6316030B1 (en) * | 1998-10-14 | 2001-11-13 | Cognis Deutschland Gmbh | Use of nanoscale sterols and sterol esters |
US20020111466A1 (en) * | 2000-12-15 | 2002-08-15 | Hendler Sheldon S. | Isoflavone derivatives |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2639293A1 (en) * | 1976-09-01 | 1978-03-02 | Henkel Kgaa | STABLE AQUATIC OR Aqueous-ALCOHOLIC SOLUTIONS OF FAT-SOLUBLE PERFUME OILS OR MEDICINAL PRODUCTS |
JPS5742616A (en) * | 1980-08-27 | 1982-03-10 | Furointo Sangyo Kk | Ubiquinone pharmaceutical having improved absorption |
JPS63188623A (en) * | 1987-01-31 | 1988-08-04 | Taisho Pharmaceut Co Ltd | Ubidecarenone preparation having improved absorption |
JPH0196109A (en) * | 1987-10-06 | 1989-04-14 | Lion Corp | Skin-beautifying cosmetic |
DD295761A5 (en) * | 1990-06-25 | 1991-11-14 | Berlin-Chemie Gmbh,De | METHOD FOR PRODUCING AMINO-RESIN MICRO-CAPSELEDISPESIONS FOR COSMETIC PREPARATES |
AU658608B2 (en) * | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
ES2229443T3 (en) * | 1997-08-22 | 2005-04-16 | Unilever N.V. | PROCEDURE FOR THE PRODUCTION OF ESTANOL ESTERES. |
DE69827330T2 (en) * | 1997-08-22 | 2006-02-02 | Unilever N.V. | Stanol ester-containing composition |
US6423363B1 (en) * | 1997-08-22 | 2002-07-23 | Lipton, Division Of Conopco, Inc. | Aqueous dispersion |
FI974648A (en) * | 1997-09-09 | 1999-05-06 | Raisio Benecol Oy | Hydroxy acid, lactic acid and hydroxyalkanoate esters and their uses |
BR9908891A (en) * | 1998-03-18 | 2001-10-02 | Kemin Ind Inc | Processes to increase the absorption and bioavailability of carotenoids in humans and poultry, to increase the deposition of carotenoids in poultry tissues and egg yolks, and to increase the deposition of carotenoids in tissues, including blood and the macular region of the retina , from humans, and, food supplement to increase the absorption and bioavailability of carotenoids in humans and poultry |
US6316130B1 (en) * | 1998-07-04 | 2001-11-13 | Bayer Aktiengesellschaft | Electroluminescent assemblies using azomethine-metal complexes |
US6423354B1 (en) * | 2000-09-01 | 2002-07-23 | Woodrow C. Monte | Low pH antimicrobial food composition from total milk protein and process of manufacturing same |
US7182950B2 (en) * | 2002-06-12 | 2007-02-27 | Nutralease Ltd. | Nano-sized self-assembled liquid dilutable vehicles |
-
2002
- 2002-01-03 US US10/037,573 patent/US20030129253A1/en not_active Abandoned
- 2002-12-30 WO PCT/US2002/041781 patent/WO2003057157A2/en not_active Application Discontinuation
- 2002-12-30 AU AU2002364054A patent/AU2002364054A1/en not_active Abandoned
-
2003
- 2003-10-03 US US10/678,557 patent/US20040067260A1/en not_active Abandoned
-
2007
- 2007-11-07 US US11/936,430 patent/US20080261927A1/en not_active Abandoned
-
2012
- 2012-04-11 US US13/444,557 patent/US20120195871A1/en not_active Abandoned
-
2013
- 2013-03-21 US US13/848,314 patent/US20130216512A1/en not_active Abandoned
-
2014
- 2014-07-22 US US14/338,145 patent/US9775910B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886294A (en) * | 1973-03-12 | 1975-05-27 | Hoffmann La Roche | Carotenoid coloring compositions and preparation thereof |
US4048203A (en) * | 1976-12-06 | 1977-09-13 | Thomas Philip | Purification of lutein-fatty acid esters from plant materials |
US6316030B1 (en) * | 1998-10-14 | 2001-11-13 | Cognis Deutschland Gmbh | Use of nanoscale sterols and sterol esters |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6190720B1 (en) * | 1999-06-15 | 2001-02-20 | Opta Food Ingredients, Inc. | Dispersible sterol compositions |
US20020111466A1 (en) * | 2000-12-15 | 2002-08-15 | Hendler Sheldon S. | Isoflavone derivatives |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8147825B2 (en) | 2004-01-22 | 2012-04-03 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US20080299100A1 (en) * | 2004-01-22 | 2008-12-04 | University Of Miami | Topical Co-Enzyme Q10 Formulations and Methods of Use |
US8771680B2 (en) | 2004-01-22 | 2014-07-08 | University Of Miami | Topical co-enzyme Q10 formulations and methods of use |
US8586030B2 (en) | 2004-01-22 | 2013-11-19 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US8562976B2 (en) | 2004-01-22 | 2013-10-22 | University Of Miami | Co-enzyme Q10 formulations and methods of use |
US20060088645A1 (en) * | 2004-10-22 | 2006-04-27 | Access Business Group International Llc | Omega-3 food product and related method of manufacture |
US20070026126A1 (en) * | 2005-08-01 | 2007-02-01 | Bryan Hitchcock | Sterol fortified beverages |
US20070110874A1 (en) * | 2005-11-17 | 2007-05-17 | Pepsico, Inc. | Beverage clouding system and method |
US7601380B2 (en) | 2005-11-17 | 2009-10-13 | Pepsico, Inc. | Beverage clouding system and method |
US20080124387A1 (en) * | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
US20110111009A1 (en) * | 2006-11-27 | 2011-05-12 | Zomanex Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
US8454945B2 (en) | 2007-03-22 | 2013-06-04 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
US10588859B2 (en) | 2007-03-22 | 2020-03-17 | Berg Llc | Topical formulations having enhanced bioavailability |
US20110059164A1 (en) * | 2008-01-04 | 2011-03-10 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110052680A1 (en) * | 2008-01-04 | 2011-03-03 | AVERA, Inc. | Encapsulation of oxidatively unstable compounds |
US8741337B2 (en) | 2008-01-04 | 2014-06-03 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US20110020519A1 (en) * | 2008-01-04 | 2011-01-27 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
US10668028B2 (en) | 2008-04-11 | 2020-06-02 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
US20110027247A1 (en) * | 2009-05-11 | 2011-02-03 | Niven Rajin Narain | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme q10) |
US10351915B2 (en) | 2009-05-11 | 2019-07-16 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (Coenzyme Q10) |
US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US9896731B2 (en) | 2009-05-11 | 2018-02-20 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US11028446B2 (en) | 2009-05-11 | 2021-06-08 | Berg Llc | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) |
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
US10376477B2 (en) | 2011-04-04 | 2019-08-13 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US11452699B2 (en) | 2011-04-04 | 2022-09-27 | Berg Llc | Method of treating or preventing tumors of the central nervous system |
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
US9901542B2 (en) | 2013-09-04 | 2018-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
US11298313B2 (en) | 2013-09-04 | 2022-04-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
Also Published As
Publication number | Publication date |
---|---|
US20130216512A1 (en) | 2013-08-22 |
WO2003057157A3 (en) | 2004-04-08 |
US20140328928A1 (en) | 2014-11-06 |
WO2003057157A2 (en) | 2003-07-17 |
AU2002364054A8 (en) | 2003-07-24 |
US20080261927A1 (en) | 2008-10-23 |
US20030129253A1 (en) | 2003-07-10 |
US9775910B2 (en) | 2017-10-03 |
US20120195871A1 (en) | 2012-08-02 |
AU2002364054A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9775910B2 (en) | Stable aqueous suspension | |
US6086915A (en) | Compositions and methods of adjusting steroid hormone metabolism through phytochemicals | |
EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
EP1916998B1 (en) | Sterol ester powder | |
PL191389B1 (en) | Sitostand formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same | |
US20050244488A1 (en) | Methods and formulations for enhansing the absorption and gastro-intestinal bioavailability of hydrophobic drugs | |
US9107825B2 (en) | Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs | |
CN101102751B (en) | Reverse micelle composition for delivery of metal cations comprising a diglyceride and a phytosterol and method of preparation | |
JP2003520204A (en) | Cholesterol lowering stanol composition, preparation and use | |
US20030003131A1 (en) | Method for manufacture of free-flowing powder containing water-dispersible sterols | |
US6455072B1 (en) | Stable aqueous dispersion of nutrients | |
WO2005051290A2 (en) | Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone | |
CA2713380C (en) | Compositions of phytosterols with enhanced bioavailability | |
WO2001037781A2 (en) | A stable aqueous dispersion of nutrients | |
JPH07112979B2 (en) | Active oxygen free radical scavenger | |
KR102393620B1 (en) | manufacturing method of nanoemulsion composition containing quercein and nanoemulsion composition containing quercein prepared using the method | |
DE60125220T2 (en) | COMPOUNDS CONTAINING A PHYTOSTEROL AND / OR A PHYTOSTANOL PART AND ASCORBIC ACID AND THEIR USE AS WEIGHT REGULATORS | |
TWI244376B (en) | Method of emulsifying phytosterol by natural saponins, emulsion prepared thereby and water dispersible phytosterol powder product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |